CARB-X supports early development of innovative products within direct-acting therapeutics for Gram-negative infections, diagnostics, prevention (includes vaccines, antibodies, microbiome, devices, etc.), indirect acting therapeutics, and direct-acting therapeutics for Gram-positive infections. The focus will be on the following areas of the product development pipeline:
GAMRIF is focussed on projects (or work packages of projects) which support the economic development and welfare of developing countries through Official Development Assistance (ODA). If a program is selected by the CARBX for investment, part of the funding for a project could come from GAMRIF funds which will be focused on those projects which:
2. meet the following GAMRIF scope: development of alternatives to traditional antibiotics(as defined in Czaplewski et al, Lancet 2016) including vaccines for infection prevention. The scope of the UK GAMRIF funds does not include diagnostics/devices.
This call is open today (1 June). Applicants must register their Expression of Interest (EoI) with CARB-X by 8 June. If researchers don’t submit their EOI, they will not be able to apply at the next stage. Short and long-form application stages will follow.
In the EOI form, applicants will be requested to indicate whether the intent of their project, or a portion of it, aligns with the ODA requirements and a detailed justification of the rationale for the eligibility is to be provided at the Short Form stage.
CARB-X can support products under development in academic or non-commercial drug development centres, but organizations with a track record of transitioning products from pre-clinical development to clinical research are of particular interest.